Announcements Trials
Browse Landscape

Phase

Phase 2/3 2Phase 2 2Phase 3 1Phase 1/2 1Phase 1 1

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Pancreatic Neoplasms 3Breast Neoplasms 2Biliary Tract Neoplasms 2Triple Negative Breast Neoplasms 1Neoplasms 1Malignant Tumor of Pancreas Metastatic to Liver 1Cholangiocarcinoma 1

Interventions

Gemcitabine 4Cisplatin 4Capecitabine 4Oxaliplatin 3Leucovorin 2Fluorouracil 2Albumin-Bound Paclitaxel 2titanium silicide 1tegafur-gimeracil-oteracil 1surufatinib 1pembrolizumab 1mitazalimab 1durvalumab 1cediranib 1anlotinib 1Taxes 1S 1 (combination) 1Paclitaxel 1Folfox protocol 1Control Groups 1ARRY-334543 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2/3 × Biliary Tract Neoplasms × Albumin-Bound Paclitaxel × Clear all
NCT06037980 2025-02-17

PURITY

Gruppo Oncologico del Nord-Ovest

Phase 2/3 Recruiting
300 enrolled
Gastrointestinal

Biliary Tract Neoplasms, Cholangiocarcinoma

NCT06662877 2024-10-29

Anlotinib Plus Nab-Paclitaxels and S-1 for Patients with Advanced Biliary Tract Cancer As Second-Line Treatment

Sun Yat-sen University

Phase 2/3 Not yet recruiting
206 enrolled
Gastrointestinal

Biliary Tract Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡